ACORN Research has expanded its research footprint to support advances in personalized medicine and translational research, by offering high-quality biospecimens coupled with premium data to industry and academic research through its partnership with AdeptBio.
ACORN Research is able to provide CRO services as needed to facilitate prospective collections of biospecimens from targeted study populations. "Development of new targeted therapies and companion diagnostics rely on availability of tissues, and increasingly biofluids, linked to deep clinical data. Banked samples are less able to meet this need, and therefore our model is aimed at optimizing prospective collections," said Dr. Lee Schwartzberg, president of ACORN Research.
Leif Honda, AdeptBio CEO, adds, "Researcher's needs are changing as biomarkers and companion diagnostics emerge along with new regulatory requirements. AdeptBio's relationship with ACORN Research presents an end-to-end answer to meet those needs. We are delighted to be entering into this partnership with ACORN Research as a CRO with an excellent history of success with its clients and rapport with their oncology network."